Switzerland· 68464001
Orladeyo 150 mg, Hartkapseln
A berotralstat product containing berotralstatum, registered in Switzerland by BioCryst Schweiz GmbH and dispensed under Swissmedic category B, on the national reimbursement list. The same ATC class is registered in 17 of our 19 countries.
Checked against Swissmedic (Switzerland) on
Informational only — not a medical device.
Where it is registered
Berotralstat is registered in 17 of 19 countries.
Countries holding a registration under ATC B06AC06 (berotralstat), each read from that country’s own register.
- This record: Switzerland, from Swissmedic (Switzerland)
- 11 of them publish a price we can compare per daily dose
Berotralstat · ATC B06AC06
17 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Franceprice
- Icelandprice
- Ireland
- Italyprice
- Japan
- Netherlands
- Norwayprice
- Polandprice
- Spainprice
- Switzerlandprice
- United Kingdom
- United Statesprice
Price per daily dose
What a daily dose of berotralstat costs, country by country.
Normalised to the WHO defined daily dose (0.15 g), so markets compare like for like.
- Switzerland: $576.89 per daily dose (median across products in the class)
- Public list prices, converted to USD at the rate date shown
Berotralstat · price per daily dose (0.15 g)
USD · FX 28 Sept 2026
- CH Switzerland$576.89
The record
At a glance
Swissmedic (Switzerland)- Active substance
- berotralstatum
- Manufacturer
- BioCryst Schweiz GmbH
- Country
- Switzerland (CH)
- ATC code
- B06AC06
- ATC class
- Berotralstat
- Defined daily dose
- 0.15 g, O
- Swissmedic category
- B
- Reimbursed
- Yes
- Source register
- Swissmedic (Switzerland)
- Last checked
- September 12, 2026
Packs & prices · 1
1 priced- gtin768068464001828 StkCHF 13396.1
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
209 interactions on record for berotralstat.
Graded by severity as the source publishes them — 66 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Berotralstat · interactions on record
209 records
- 66 severe
- 132 moderate
- 11 minor
Most severe, free to view
- RolapitantA04AD14severe
- NaloxegolA06AH03severe
- FidaxomicinA07AA12severe
- EliglustatA16AX10severe
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same medicine, other countries
Berotralstat in 15 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- CzechiaORLADEYOBIOCRYST IRELAND LIMITED, Dublin
- United StatesOrladeyoBioCryst Pharmaceuticals, Inc.
- SpainORLADEYO 150 MG CAPSULAS DURASBiocryst Ireland Limited
- FinlandOrladeyoBioCryst Ireland Limited
- FranceORLADEYO 150 mg, géluleBIOCRYST IRELAND LIMITED (IRLANDE)
- BelgiumOrladeyo 150 mgBiocryst Ireland
- IcelandOrladeyoBioCryst Ireland Limited
- NetherlandsOrladeyo 150 mg, harde capsuleBioCryst Ireland Ltd
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Orladeyo
- Liechtenstein · Orladeyo
- Norway · Orladeyo
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Swissmedic (Switzerland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/07bd8e8d-55e1-4bd6-ac38-f98f06c22dbd GET /v1/drugs/07bd8e8d-55e1-4bd6-ac38-f98f06c22dbd?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"unit": null,
"strength": "berotralstatum 150 mg",
"valid_from": "2022-07-01",
"limitations": "[{\"description\":\"Nach Kostengutsprache des Krankenversicherers mit vorgängiger Konsultation des Vertrauensarztes.<br>\\nORLADEYO wird vergütet als Monotherapie bei Patienten ab einem Alter von 12 Jahren zur routinemässigen Prävention wiederkehrender Attacken des hereditären Angioödems (HAE).<br>\\nDie Einleitung und Überwachung der Behandlung erfolgt ausschliesslich über eines der folgenden Zentren: Universitätsspital Zürich, Inselspital Bern, Universitätsspital Basel, CHUV, HUG, Kantonsspital Luzern, Kantonsspital Aarau und Kantonsspital St. Gallen.<br>\\n<br>\\n\",\"costApproval\":null,\"indication\":\"\",\"isNew\":false,\"limitationCode\":null,\"priceModel\":null,\"validFrom\":\"2022-07-01\"}]",
"galenic_form": "Kaps 150 mg",
"therapeutic_area": null,
"sl_inclusion_date": "2022-07-01",
"self_retention_pct": 10
}See everything about berotralstat.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.